Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

Medical science monitor : international medical journal of experimental and clinical research - 8 May 2018

Song Hao, Zhang Jinna, Ning Liang, Zhang Honglai, Chen Dong, Jiao Xuelong, Zhang Kejun

Abstract excerpt

BACKGROUND [i]BRAF[/i]V600E mutation occurs in approximately 45% of papillary thyroid cancer (PTC) cases, and 25% of anaplastic thyroid cancer (ATC) cases. Vemurafenib/PLX4032, a selective BRAF inhibitor, suppresses extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 (MEK/ERK1/2) signaling and shows beneficial effects in patients with metastatic melanoma harboring the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Mice, SCID

Share to Mitogen-Activated Protein Kinase Kinases

Share to Sulfonamides

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29737325
DOI: 10.12659/MSM.910084
PMCID: PMC5965018

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.PMID 29737325Read ↗

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.Semantic proximity Read ↗

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation.Semantic proximity Read ↗

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.